すべての画像(1)
About This Item
実験式（ヒル表記法）:
C14H11ClN2O4S
CAS番号:
分子量:
338.77
MDL番号:
UNSPSCコード:
41116107
PubChem Substance ID:
NACRES:
NA.24
おすすめの製品
グレード
pharmaceutical primary standard
APIファミリー
chlorthalidone
メーカー／製品名
EDQM
アプリケーション
pharmaceutical (small molecule)
フォーマット
neat
保管温度
2-8°C
SMILES記法
NS(=O)(=O)c1cc(ccc1Cl)C2(O)NC(=O)c3ccccc23
InChI
1S/C14H11ClN2O4S/c15-11-6-5-8(7-12(11)22(16,20)21)14(19)10-4-2-1-3-9(10)13(18)17-14/h1-7,19H,(H,17,18)(H2,16,20,21)
InChI Key
JIVPVXMEBJLZRO-UHFFFAOYSA-N
遺伝子情報
human ... SLC12A3(6559)
類似した製品をお探しですか？ 訪問 製品比較ガイド
詳細
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
アプリケーション
Chlorthalidone EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
その他情報
Sales restrictions may apply.
関連製品
製品番号
詳細
価格
シグナルワード
Warning
危険有害性情報
危険有害性の分類
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
ターゲットの組織
Respiratory system
保管分類コード
11 - Combustible Solids
WGK
WGK 2
引火点(°F)
Not applicable
引火点(℃)
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
C1950000-1EA:
C1950000:
最新バージョンのいずれかを選択してください：
Edarbyclor: an ARB/chlorthalidone combination for hypertension.
The Medical letter on drugs and therapeutics, 54(1385), 17-18 (2012-03-03)
James R Singer et al.
Journal of glaucoma, 24(1), 84-86 (2014-01-23)
To report a novel case of acute bilateral uveal effusions, angle closure, and acute myopia induced by administration of chlorthalidone. Case report. Bilateral shallow anterior chambers, high intraocular pressure, and a myopic shift were encountered in a patient 1 week
George C Roush et al.
Current hypertension reports, 15(5), 514-521 (2013-07-11)
How chlorthalidone (CTDN) reduces risk for cardiovascular events (CVEs) can be considered in light of its ability to lower blood pressure (BP) and its non-BP related, pleiotropic effects. The mechanism by which CTDN lowers BP is unclear but may include
Kimberly M Neff et al.
Cardiology in review, 18(1), 51-56 (2009-12-17)
Thiazide diuretics are a mainstay for the treatment of hypertension. Although there are several thiazide diuretics currently available, hydrochlorothiazide (HCTZ) continues to be the most popular thiazide used for treating high blood pressure. This is despite several clinical trials that
Barry L Carter et al.
Hypertension (Dallas, Tex. : 1979), 43(1), 4-9 (2003-11-26)
Thiazide diuretics are one of the preferred pharmacologic treatments for hypertension. Hydrochlorothiazide and chlorthalidone have been the 2 most commonly used diuretics in major clinical trials. Treatment guidelines and compendia often consider these 2 drugs interchangeable agents within the class
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）